1.Primary synovial sarcoma of lung: a clinicopathological analysis of 12 cases.
X W ZHANG ; J G WEI ; J P SUN ; Z G XU ; Q CHENG ; L ZHANG ; L F KONG
Chinese Journal of Pathology 2023;52(11):1120-1125
Objective: To investigate the clinicopathological features, immunophenotype, molecular features and differential diagnosis of primary synovial sarcoma of the lung (PSSL). Methods: Twelve cases of PSSL were collected at Henan Provincial People's Hospital, during May 2010 and April 2021, and their clinicopathological parameters were summarized. SS18-SSX, H3K27Me3, and SOX2 were added to the original immunomarkers to evaluate their diagnostic value for PSSL. Results: The age of 12 patients when diagnosed ranged from 32 to 75 years (mean of 50 years). There were 7 males and 5 females, 2 left lung cases and 10 right lung cases. Of the 6 patients who underwent surgical resection, five cases were confined to lung tissue (T1), one case had mediastinal invasion (T3), two cases had regional lymph node metastasis (N1), and none had distal metastasis. Microscopically, 11 cases showed monophasic spindle cell type and one case showed biphasic type composed of mainly epithelial cells consisting of cuboidal to columnar cells with glandular and cribriform structures. It was difficult to make the diagnosis by using the biopsy specimens. Immunohistochemistry (IHC) showed CKpan expression in 8 of 12 cases; EMA expression in 11 of 12 case; TLE1 expression in 8 of 12 cases; S-100 protein expression in two of 12 cases; various expression of bcl-2 and vimentin in 12 cases, but no expression of SOX10 and CD34 in all the cases. The Ki-67 index was 15%-30%. The expression of SS18-SSX fusion antibody was diffusely and strongly positive in all 12 cases. SOX2 was partially or diffusely expressed in 8 of 12 cases, with strong expression in the epithelial component. H3K27Me3 was absent in 3 of 12 cases. SS18 gene translocation was confirmed by fluorescence in situ hybridization (FISH) test in all 12 samples. Six cases underwent surgery and postoperative chemotherapy, while the other six cases had chemotherapy alone. Ten patients were followed up after 9-114 months, with an average of 41 months and a median of 26 months. Five patients survived and five died of the disease within two years. Conclusions: PSSL is rare and has a broad morphological spectrum. IHC and molecular tests are needed for definitive diagnosis. Compared with current commonly used IHC markers, SS18-SSX fusion antibody has better sensitivity to PSSL, which could be used as an alternative for FISH, reverse transcription-polymerase chain reaction or next generation sequencing in the diagnosis of PSSL.
Male
;
Female
;
Humans
;
Adult
;
Middle Aged
;
Aged
;
Biomarkers, Tumor/analysis*
;
Sarcoma, Synovial/diagnosis*
;
In Situ Hybridization, Fluorescence
;
Histones/genetics*
;
Proto-Oncogene Proteins/metabolism*
;
Oncogene Proteins, Fusion/genetics*
;
Repressor Proteins/metabolism*
;
Lung/pathology*
;
Lung Neoplasms
5.Expressions of HELQ and RAD51C in endometrial stromal sarcoma and their clinical significance.
Ying LIU ; Yu ZHANG ; Yan TIAN
Journal of Zhejiang University. Medical sciences 2020;40(7):936-941
OBJECTIVE:
To observe the expression of HELQ and RAD51C in normal endometrial and endometrial stromal sarcoma (ESS) and analyze their correlation with the clinical features of the patients.
METHODS:
The expressions of HELQ and RAD51C proteins were detected by immunohistochemical staining in normal endometrial tissues (14 cases) and tumor tissues from patients with ESS (37 cases) treated in Hunan Provincial Cancer Hospital from January, 2013 to December, 2016. The correlations of the expressions of the two proteins with the patients'age, FIGO staging, tissue type, tumor size, and lymph node metastasis were analyzed.
RESULTS:
Immunohistochemical staining showed that the expressions of HELQ and RAD51C were both decreased in ESS patients compared with the normal group, and there was a positive correlation between HELQ and RAD51C expression ( < 0.05). HELQ expression in ESS was correlated with the tumor size and type. The expressions of HELQ and RAD51C were not correlated with the patients' age, FIGO stage and status of lymph node metastasis ( > 0.05).
CONCLUSIONS
Homologous recombination- directed DNA repair involving HELQ and RAD51C may participate in the occurrence and progression of ESS.
DNA Helicases
;
genetics
;
DNA-Binding Proteins
;
genetics
;
Endometrial Neoplasms
;
diagnosis
;
physiopathology
;
Endometrium
;
physiopathology
;
Female
;
Gene Expression Regulation, Neoplastic
;
Humans
;
Lymphatic Metastasis
;
physiopathology
;
Sarcoma, Endometrial Stromal
;
physiopathology
6.Clear cell odontogenic carcinoma: a mini review
Young Hwan KIM ; Eun Jin SEO ; Jae Kyung PARK ; Il Ho JANG
International Journal of Oral Biology 2019;44(3):77-80
Clear cell odontogenic carcinoma (CCOC), a very rare neoplasm located mostly in the mandible, has been regarded as a benign tumor. However, due to the accumulation of case reports, CCOC has been reclassified as a malignant entity by the World Health Organization. Patients with CCOC present with regional swelling and periodontal indications with variable pain, often remaining misdiagnosed for a long period. CCOC has slow growth but aggressive behavior, requiring radical resection. Histologic analysis revealed the monophasic, biphasic, and ameloblastic types of CCOC with clear cells and a mixed combination of polygonal and palisading cells. At the molecular level, CCOC shows the expression of cytokeratin and epithelial membrane antigen, along with markers that assign CCOC to the sarcoma family. At the genetic level, Ewing sarcoma breakpoint region 1-activating transcription factor 1 fusion is regarded as the key feature for identification. Nevertheless, the scarcity of cases and dependence on histological data delay the development of an efficient therapy. Regarding the high recurrence rate and the potential of distant metastasis, further characterization of CCOC is necessary for an early and accurate diagnosis.
Ameloblasts
;
Diagnosis
;
Humans
;
Keratins
;
Mandible
;
Mucin-1
;
Neoplasm Metastasis
;
Odontogenic Tumors
;
Recurrence
;
Sarcoma
;
Sarcoma, Ewing
;
Transcription Factors
;
World Health Organization
7.Current Status of Magnetic Resonance Imaging in Patients with Malignant Uterine Neoplasms: A Review.
Yu Ting HUANG ; Yen Ling HUANG ; Koon Kwan NG ; Gigin LIN
Korean Journal of Radiology 2019;20(1):18-33
In this study, we summarize the clinical role of magnetic resonance imaging (MRI) in the diagnosis of patients with malignant uterine neoplasms, including leiomyosarcoma, endometrial stromal sarcoma, adenosarcoma, uterine carcinosarcoma, and endometrial cancer, with emphasis on the challenges and disadvantages. MRI plays an essential role in patients with uterine malignancy, for the purpose of tumor detection, primary staging, and treatment planning. MRI has advanced in scope beyond the visualization of the many aspects of anatomical structures, including diffusion-weighted imaging, dynamic contrast enhancement-MRI, and magnetic resonance spectroscopy. Emerging technologies coupled with the use of artificial intelligence in MRI are expected to lead to progressive improvement in case management of malignant uterine neoplasms.
Adenosarcoma
;
Artificial Intelligence
;
Carcinosarcoma
;
Case Management
;
Diagnosis
;
Endometrial Neoplasms
;
Female
;
Humans
;
Leiomyosarcoma
;
Magnetic Resonance Imaging*
;
Magnetic Resonance Spectroscopy
;
Sarcoma
;
Sarcoma, Endometrial Stromal
;
Uterine Neoplasms*
8.Stage and histology of cervical cancer in women under 25 years old
Diama Bhadra VALE ; Lucas Almeida CAVALCANTE ; Liliana Aparecida Lucci De Angelo ANDRADE ; Julio Cesar TEIXEIRA ; Talita Lourenço do Rio MENIN ; Luiz Carlos ZEFERINO
Journal of Gynecologic Oncology 2019;30(4):e55-
OBJECTIVE: To evaluate the histological and stage characteristics of cervical cancer in women under 25 years old, and to compare them with older women. METHODS: Cross-sectional study of cases from the Hospital Cancer Registry of São Paulo State/Brazil from 2000 to 2015. Variables were age, International Federation of Gynecology and Obstetrics stage and histological type. Prevalence ratio (PR) and its 95% confidence interval (CI) were calculated. RESULTS: Out of 18,423 cervical cancer cases 204 (1.1%) were in women under 25 years old. The most frequent stage was stage I in women under 25 (36.2%) and between 25 and 34 (43.4%), and stage III in older women (31.8%). No statistically significant difference was observed in stages by age group. Squamous carcinomas were the most frequent in 73.5% of women under 25 and 78.5% of older women. In women under 25 the following histological types were more frequent: neuroendocrine carcinomas (PR=6.10, 95% CI=2.03–18.35), malignant germ cell tumors (PR=54.98, 95% CI=26.53–113.95), mesenchymal tumors (sarcomas) (PR=5.67, 95% CI=2.58–12.45) and hematopoietic/lymphoid tumors (PR=0.72, 95% CI=2.90–36.69). CONCLUSION: In women under 25 years old cervical cancer was an uncommon diagnosis and in about one third occurred at early stage. Squamous carcinoma was the most frequent histological type regardless age, but rare histological types were more frequent in young women.
Carcinoma, Neuroendocrine
;
Carcinoma, Squamous Cell
;
Cross-Sectional Studies
;
Diagnosis
;
Female
;
Gynecology
;
Humans
;
Neoplasm Staging
;
Neoplasms, Germ Cell and Embryonal
;
Obstetrics
;
Prevalence
;
Sarcoma
;
Uterine Cervical Neoplasms
;
Young Adult
9.Primary Rhabdomyosarcoma of the Breast: Study of Three Cases at One Institution with a Review of Primary Breast Sarcomas
Junyoung SHIN ; Hee Jeong KIM ; Dae Yeon KIM ; Gyungyub GONG ; Kyung Ja CHO
Journal of Pathology and Translational Medicine 2019;53(5):308-316
BACKGROUND: Primary breast sarcoma (PBS) is rare, comprising approximately 1% of breast malignancies. Rhabdomyosarcoma (RMS) accounts for an extremely small proportion of PBSs, often leading to delayed histologic confirmation. METHODS: Upon reviewing Asan Medical Center’s pathology database between 2000 and 2018, 41 PBS cases were retrieved, including three cases of primary RMS of the breast. Their clinicopathological features were analyzed, and the literature related to PBS and primary RMS of the breast was reviewed. RESULTS: We identified three primary breast RMS cases from our institution database, comprising 7.3% of PBS: one case each of spindle cell/sclerosing RMS (ssRMS), alveolar RMS (aRMS), and embryonal RMS (eRMS). All cases involved adolescents or young adults (14, 16, and 25 years, respectively) who underwent mastectomy or radiotherapy and were confirmed using immunohistochemical testing for myogenin, desmin, and myogenic differentiation. The ssRMS patient experienced recurrence at the operation site 4 months post-surgery despite undergoing concurrent chemoradiotherapy. The aRMS patient had multiple metastases at diagnosis and showed FAX3-FOXO1 fusion transcripts; she died 22 months after the diagnosis. The eRMS patient had enlarged axillary lymph nodes; post-radiotherapy, the lesion recurred as multiple metastases to the bone and lung. She died 18 months post-diagnosis. CONCLUSIONS: Our experience on RMS cases suggests that spindle cell or small round cell malignancy in breasts of young female should raise suspicion for the possibility of primary or secondary RMS. To our knowledge, this is the second report of primary breast ssRMS and it may help clinicians who encounter this rare disease in the future.
Adolescent
;
Arm
;
Breast
;
Chemoradiotherapy
;
Chungcheongnam-do
;
Desmin
;
Diagnosis
;
Female
;
Humans
;
Lung
;
Lymph Nodes
;
Mastectomy
;
Myogenin
;
Neoplasm Metastasis
;
Pathology
;
Radiotherapy
;
Rare Diseases
;
Recurrence
;
Rhabdomyosarcoma
;
Sarcoma
;
Young Adult
10.Menopausal hormone therapy in the cancer survivors
Journal of the Korean Medical Association 2019;62(3):160-166
Due to advances in the treatment and diagnosis of cancer, many women survive long after treatment, and therefore express concerns about the impact of estrogen deficiency on their quality of life. Cancer treatment can induce menopause through surgical removal of the ovaries, chemotherapy, or radiation. Women who undergo induced menopause usually experience more sudden and severe menopausal symptoms, including vasomotor symptoms, psychological symptoms, genitourinary symptoms, cardiovascular disease, and osteoporosis. Menopausal hormone therapy (MHT) is especially important in women younger than 40. In this review, we consider the role of MHT after the diagnosis of breast, gynecologic, colorectal, stomach, liver, lung, and hematologic cancers. MHT is advantageous in endometrial cancer type I, cervical squamous cell carcinoma, colorectal cancer, hepatocellular carcinoma, and hematologic malignancies. However, MHT is not recommended for use in breast cancer, endometrial stromal sarcoma, hormone receptor–positive gastric cancer, and lung cancer survivors because it is linked to an increased risk of cancer recurrence. Depending on the type of cancer, clinicians should recommend that cancer survivors receive appropriate MHT in order to reduce vasomotor symptoms and to benefit from its positive effects on the cardiovascular and skeletal systems.
Breast
;
Breast Neoplasms
;
Carcinoma, Hepatocellular
;
Carcinoma, Squamous Cell
;
Cardiovascular Diseases
;
Colorectal Neoplasms
;
Diagnosis
;
Drug Therapy
;
Endometrial Neoplasms
;
Estrogens
;
Female
;
Hematologic Neoplasms
;
Humans
;
Liver
;
Lung
;
Lung Neoplasms
;
Menopause
;
Osteoporosis
;
Ovary
;
Quality of Life
;
Recurrence
;
Sarcoma, Endometrial Stromal
;
Stomach
;
Stomach Neoplasms
;
Survivors

Result Analysis
Print
Save
E-mail